VivoSeq
Other

Transplant Recipient

0

Pipeline Programs↗

11

Active Trials↗

10

Companies Involved↗

Transplant Recipient is an early-stage landscape with 0 programs across 10 companies. The most active players are Novartis, Roche, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

71/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalAmgen logo

Amgen

0 programs

PreclinicalJazz Pharmaceuticals logo

Jazz Pharmaceuticals

0 programs

PreclinicalTakeda logo

Takeda

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

54

clinical trials

Completed29 · 54%
Recruiting8 · 15%
Withdrawn6 · 11%
Terminated6 · 11%
Unknown status2 · 4%
Active, not recruiting2 · 4%
Other1 · 2%

Clinical Trials

Trial Activity

54 trials

Levothyroxine Supplementation for Heart Transplant Recipients
Recruiting·UUniversity of California, San Francisco·Phase 1·NCT06428097·97 enrolled
A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients
Recruiting·TThe University of Queensland·Phase 3·NCT05325008·280 enrolled
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Recruiting·UUniversity of Wisconsin, Madison·Phase 3·NCT06407232·90 enrolled
Randomized Trial of SGLT2i in Heart Transplant Recipients
Recruiting·VVA Office of Research and Development·Phase 4·NCT06625073·200 enrolled
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
Recruiting·UUniversity of Pennsylvania·Phase 2·NCT06066957·80 enrolled
Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients
Recruiting·UUniversity Medical Centre Ljubljana·Phase 2·NCT05432778·90 enrolled
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
Recruiting·—·N/A·NCT01999361·18 enrolled
RSV Vaccine in Transplant Recipients
Recruiting·UUniversity Health Network, Toronto·Phase 3·NCT06593210·100 enrolled
Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients
Active, not recruiting·UUniversity of Arizona·Phase 2·NCT05699603·56 enrolled
Immunogenicity of HPV Vaccine in Transplant Recipients.
Active, not recruiting·MMedical College of Wisconsin·Phase 4·NCT05557370·30 enrolled
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
Enrolling by invitation·UUniversidade Federal do Ceara·Phase 2·NCT06147271·80 enrolled
Letermovir Use in Heart Transplant Recipients
Completed·TTufts Medical Center·Phase 4·NCT04904614·32 enrolled
Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients
Completed·UUniversity of Saskatchewan·Phase 4·NCT04023760·14 enrolled
Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients
Completed·UUniversity Health Network, Toronto·N/A·NCT03401268·20 enrolled
Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
Completed·FFundacion SEIMC-GESIDA·Phase 4·NCT01303549·61 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)